Comparable stake leader
ARK Investment Management LLC
SEC ownership of CRISPR Therapeutics AG
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001674416.
Disclosed value leader
ARK Investment Management LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- CRSP on Nasdaq
- Parsed ownership sources
-
13D/G and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
ARK Investment Management LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
ARK Investment Management LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001674416
- Issuer location
- Zug
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of CRISPR Therapeutics AG (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARK Investment Management...
Disclosed value leader
ARK Investment Management...
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
13F
Lead comparable stake: 12%
13D/G row: ARK Investment Management LLC
Showing 1-8 of 50 holder rows.
Quick read
ARK Investment Management LLC leads the comparable SEC ownership view at 12%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARK Investment Management LLC's linked filing trail.
Comparable ownership
Top 5
ARK Investment Management LLC
12%
BlackRock, Inc.
8.3%
ORBIS INVESTMENT MANAGEMENT LTD
6.3%
Capital World Investors
5.1%
Capital International Investors
1.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARK Investment Management LLC |
13D/G
13F
Company
|
12%
|
$538,189,046
11,313,623 shares
|
+$72,622,740 | 31 Mar 2026 |
| BlackRock, Inc. |
13D/G
13F
Company
|
8.3%
|
$435,625,269
7,987,262 shares
|
+$112,070,374 | 30 Jun 2026 |
| ORBIS INVESTMENT MANAGEMENT LTD |
13D/G
|
6.3%
|
$333,925,337
6,090,194 shares
|
+$8,546,133 | 31 Mar 2026 |
| Capital World Investors |
13D/G
13F
Company
|
5.1%
|
$270,280,537
4,929,428 shares
|
$0 | 31 Mar 2026 |
| Capital International Investors |
13D/G
13F
Company
|
1.2%
|
$62,235,477
1,186,794 shares
|
-$269,926,929 | 30 Jan 2026 |
| Orbis Allan Gray Ltd |
13F
Company
|
6.3%
|
$290,462,944
6,106,011 shares
|
— | 31 Mar 2026 |
| STATE STREET CORP |
13F
Company
|
4.1%
|
$189,447,525
3,982,500 shares
|
— | 31 Mar 2026 |
| GSK plc |
13F
Company
|
3.3%
|
$153,205,226
3,220,627 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$17,626,978.
Buys
$0
Insiders: 0
Sells
$17,626,978
Insiders: 4
Net
-$17,626,978
Shares: -303,157
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 303,157
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 3,786 | $0 | $210,577 | -$210,577 |
| 3-6 | 0 | 65,405 | $0 | $3,227,835 | -$3,227,835 |
| 6-9 | 0 | 164,672 | $0 | $9,617,447 | -$9,617,447 |
| 9-12 | 0 | 69,294 | $0 | $4,571,118 | -$4,571,118 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 22 reporting-owner rows connected to CRISPR Therapeutics AG. Open a relationship link for the CIK-to-CIK filing trail.
Rows
22
Largest Forms 3/4/5 holder
Simeon George
Net 12M change
-$17,626,977
Latest report
05 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Simeon George | Director | $90,021,213 | Filing P/S | 05 Jun 2026 | ||
| Rodger Novak | President, Director | $35,814,599 | Mixed | 30 Jun 2021 | ||
| Samarth Kulkarni | Chief Executive Officer, Director | $11,952,336 | -$11,517,592 | -49% | Filing P/S | 20 Mar 2026 |
| James R. Kasinger | General Counsel and Secretary | $4,411,728 | -$645,902 | -13% | Filing P/S | 29 May 2026 |
| Tony W. Ho | Executive VP, Head of R&D | $3,272,902 | Mixed | 03 Dec 2021 | ||
| Douglas A. Treco | Director | $1,254,660 | Filing P/S | 05 Jun 2026 | ||
| Naimish Patel | Chief Medical Officer | $1,076,636 | -$362,596 | -25% | Filing P/S | 29 May 2026 |
| Raju Prasad | Chief Financial Officer | $728,130 | -$5,100,887 | -88% | Filing P/S | 29 May 2026 |
| Julianne Bruno | Chief Operating Officer | $726,967 | Mixed | 20 Mar 2025 | ||
| Brendan Smith | Chief Financial Officer | $317,015 | Mixed | 18 Feb 2023 | ||
| John Greene | Director | $313,948 | Filing P/S | 05 Jun 2026 | ||
| Phuong Khanh Morrow | Chief Medical Officer | $275,700 | Mixed | 13 Oct 2023 | ||
| Briggs Morrison | Director | $195,806 | Mixed | 05 Jun 2026 | ||
| Michael John Tomsicek | Chief Financial Officer | $118,193 | Mixed | 06 Aug 2021 | ||
| Harold Edward Fleming | Director | Mixed | 05 Jun 2026 | |||
| Christian Rommel | Director | Mixed | 05 Jun 2026 | |||
| Bradley J. Bolzon PhD | Director | Mixed | 09 Jun 2022 | |||
| Lawrence Otto Klein | Cbo & Coo | Mixed | 16 Aug 2022 | |||
| Maria Fardis | Director | Mixed | 05 Jun 2026 | |||
| Ali Behbahani | Director | Mixed | 05 Jun 2026 |
Recent insider transactions for CRISPR Therapeutics AG
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Simeon George | CRSP | Stock Option (Right to Buy) | Award | 13,000 | 13,000 | 05 Jun 2026 | Direct | |||
| Ali Behbahani | CRSP | Stock Option (Right to Buy) | Award | 13,000 | 13,000 | 05 Jun 2026 | Direct | |||
| Maria Fardis | CRSP | Stock Option (Right to Buy) | Award | 13,000 | 13,000 | 05 Jun 2026 | Direct | |||
| Harold Edward Fleming | CRSP | Stock Option (Right to Buy) | Award | 13,000 | 13,000 | 05 Jun 2026 | Direct | |||
| John Greene | CRSP | Stock Option (Right to Buy) | Award | 13,000 | 13,000 | 05 Jun 2026 | Direct | |||
| Katherine A. High | CRSP | Stock Option (Right to Buy) | Award | 13,000 | 13,000 | 05 Jun 2026 | Direct | |||
| Sandesh Mahatme | CRSP | Stock Option (Right to Buy) | Award | 13,000 | 13,000 | 05 Jun 2026 | Direct | |||
| Briggs Morrison | CRSP | Stock Option (Right to Buy) | Award | 13,000 | 13,000 | 05 Jun 2026 | Direct | |||
| Christian Rommel | CRSP | Stock Option (Right to Buy) | Award | 13,000 | 13,000 | 05 Jun 2026 | Direct | |||
| Douglas A. Treco | CRSP | Stock Option (Right to Buy) | Award | 13,000 | 13,000 | 05 Jun 2026 | Direct | |||
| James R. Kasinger | CRSP | Restricted Stock Units | Award | 17,000 | 17,000 | 29 May 2026 | Direct | |||
| Naimish Patel | CRSP | Restricted Stock Units | Award | 22,000 | 22,000 | 29 May 2026 | Direct | |||
| Raju Prasad | CRSP | Restricted Stock Units | Award | 19,500 | 19,500 | 29 May 2026 | Direct | |||
| Naimish Patel | CRSP | Common Shares | Sale | -16.4% | $210,577 | $55.62 | -3,786 | 19,357 | 29 May 2026 | Direct |
| Naimish Patel | CRSP | Common Shares | Options Exercise | 76.1% | 10,000 | 23,143 | 28 May 2026 | Direct | ||
| Naimish Patel | CRSP | Restricted Stock Units | Options Exercise | -33.3% | -10,000 | 20,000 | 28 May 2026 | Direct | ||
| James R. Kasinger | CRSP | Common Shares | Sale | -3.26% | $148,854 | $46.78 | -3,182 | 94,308 | 23 Mar 2026 | Direct |
| Samarth Kulkarni | CRSP | Common Shares | Sale | -3.77% | $468,736 | $46.78 | -10,020 | 255,501 | 23 Mar 2026 | Direct |
| Raju Prasad | CRSP | Common Shares | Sale | -19.2% | $173,460 | $46.78 | -3,708 | 15,565 | 23 Mar 2026 | Direct |
| James R. Kasinger | CRSP | Common Shares | Options Exercise | 6.85% | 6,250 | 97,490 | 20 Mar 2026 | Direct | ||
| James R. Kasinger | CRSP | Restricted Stock Units | Options Exercise | -34.2% | -6,250 | 12,000 | 20 Mar 2026 | Direct | ||
| James R. Kasinger | CRSP | Restricted Stock Units | Award | 25,000 | 25,000 | 20 Mar 2026 | Direct | |||
| James R. Kasinger | CRSP | Stock Option (Right to Buy) | Award | 38,499 | 38,499 | 20 Mar 2026 | Direct | |||
| Samarth Kulkarni | CRSP | Common Shares | Options Exercise | 8.01% | 19,687 | 265,521 | 20 Mar 2026 | Direct | ||
| Samarth Kulkarni | CRSP | Restricted Stock Units | Options Exercise | -33.3% | -19,687 | 39,375 | 20 Mar 2026 | Direct | ||
| Samarth Kulkarni | CRSP | Restricted Stock Units | Award | 81,875 | 81,875 | 20 Mar 2026 | Direct | |||
| Samarth Kulkarni | CRSP | Stock Option (Right to Buy) | Award | 114,249 | 114,249 | 20 Mar 2026 | Direct | |||
| Raju Prasad | CRSP | Common Shares | Options Exercise | 48% | 6,250 | 19,273 | 20 Mar 2026 | Direct | ||
| Raju Prasad | CRSP | Restricted Stock Units | Options Exercise | -33.3% | -6,250 | 12,500 | 20 Mar 2026 | Direct | ||
| Raju Prasad | CRSP | Restricted Stock Units | Award | 27,500 | 27,500 | 20 Mar 2026 | Direct | |||
| Raju Prasad | CRSP | Stock Option (Right to Buy) | Award | 38,499 | 38,499 | 20 Mar 2026 | Direct | |||
| Naimish Patel | CRSP | Restricted Stock Units | Award | 30,000 | 30,000 | 20 Mar 2026 | Direct | |||
| Naimish Patel | CRSP | Stock Option (Right to Buy) | Award | 38,499 | 38,499 | 20 Mar 2026 | Direct | |||
| Naimish Patel | CRSP | Common Shares | Sale | -19.3% | $152,019 | $48.26 | -3,150 | 13,143 | 16 Mar 2026 | Direct |
| Raju Prasad | CRSP | Common Shares | Gift | -5.45% | -750 | 13,023 | 16 Mar 2026 | Direct | ||
| Raju Prasad | CRSP | Common Shares | Sale | -41.7% | $476,278 | $48.26 | -9,869 | 13,773 | 16 Mar 2026 | Direct |
| James R. Kasinger | CRSP | Common Shares | Sale | -3.64% | $166,497 | $48.26 | -3,450 | 91,240 | 16 Mar 2026 | Direct |
| Samarth Kulkarni | CRSP | Common Shares | Sale | -4.04% | $499,443 | $48.26 | -10,349 | 245,834 | 16 Mar 2026 | Direct |
| Naimish Patel | CRSP | Common Shares | Options Exercise | 99.5% | 8,125 | 16,293 | 14 Mar 2026 | Direct | ||
| Naimish Patel | CRSP | Restricted Stock Units | Options Exercise | -25% | -8,125 | 24,375 | 14 Mar 2026 | Direct | ||
| Raju Prasad | CRSP | Common Shares | Options Exercise | 249.4% | 16,875 | 23,642 | 14 Mar 2026 | Direct | ||
| Raju Prasad | CRSP | Restricted Stock Units | Options Exercise | -62.8% | -16,875 | 10,000 | 14 Mar 2026 | Direct | ||
| James R. Kasinger | CRSP | Common Shares | Options Exercise | 7.83% | 6,875 | 94,690 | 14 Mar 2026 | Direct | ||
| James R. Kasinger | CRSP | Restricted Stock Units | Options Exercise | -25% | -6,875 | 20,625 | 14 Mar 2026 | Direct | ||
| Samarth Kulkarni | CRSP | Common Shares | Options Exercise | 8.76% | 20,625 | 256,183 | 14 Mar 2026 | Direct | ||
| Samarth Kulkarni | CRSP | Restricted Stock Units | Options Exercise | -25% | -20,625 | 61,875 | 14 Mar 2026 | Direct | ||
| James R. Kasinger | CRSP | Common Shares | Sale | -3.09% | $147,840 | $52.80 | -2,800 | 87,815 | 11 Mar 2026 | Direct |
| Samarth Kulkarni | CRSP | Common Shares | Sale | -3.99% | $517,334 | $52.80 | -9,798 | 235,558 | 11 Mar 2026 | Direct |
| James R. Kasinger | CRSP | Common Shares | Options Exercise | 6.46% | 5,500 | 90,615 | 10 Mar 2026 | Direct | ||
| James R. Kasinger | CRSP | Restricted Stock Units | Options Exercise | -50% | -5,500 | 5,500 | 10 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.